Trial intelligence / Profile preview

BG9924 dose-finding study with methotrexate in active rheumatoid arthritis

2006-005466-39Phase 2Completed

Sponsor
Biogen
Start
Jan 2007
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of baminercept in rheumatoid arthritis (RA) (6 arms), sponsored by Biogen. Primary endpoint: ACR50 response at Week 14. Started Jan 2007; status: completed.

02

Drugs

baminercept
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2006-005466-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-005466-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call